1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Recalls

Q2 Recalls Snapshot: Recall Events Rise 31% While Recalled Units Slide

 
• By Shawn M. Schmitt

Medical device recalls initiated in the second quarter of 2020 increased 31% from the previous quarter, marking the largest number of corrections and removals in a quarter in two years. Check out our Q2 recalls infographic.

Q2 Device Recalls

Medical device recalls initiated in the second quarter of 2020 mushroomed 31% from the previous quarter, marking the largest number of corrections and removals in a quarter in two years. There were 341 recalls in Q2, compared to 260 in Q1. “While the average recall size was lower than the previous quarter, this level of recall activity puts the industry on track to experience about 1,200 recalls by year end,” consulting firm Stericycle says in its most recent recalls index. “This annual activity would represent a 35% increase over last year. And it’s worth noting that this activity does not include unofficial recalls of face masks and other personal protection equipment handled at the state level.”

Meanwhile, industry recalled 29,405,138 device units in Q2, a 92% decrease from Q1, when 355.1 million units were pulled from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Recalls

More from Policy & Regulation

MHRA’s Tallon Hails PMS Regulation As Start Of UK Device Framework Transformation

 
• By Ashley Yeo

16 June marked the first major new regulatory instrument in the UK’s post-Brexit transition to a standalone device regulatory system for Great Britain.

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By Elizabeth Orr

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.

With LDT Rule DOA, Could FDA Shift Focus To RUOs?

 
• By Brian Bossetta

Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?